- TACE combined with apatinib in patients with intermediate and advanced hepatocellular carcionma: A prospective, multi-center, randomized clinical trialLiang, B.; Ma, Y.; Huang, M.; Zhang, X.; Yu, L.; Luo, Y.; Liu, R.; Zhou, S.; Xu, G.; Li, H-L.; Liao, Z.; Xiang, H.; Lu, W.; Xu, L.; Zheng, C.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
- Donafenib combined with anti-PD-1 antibodies plus transarterial therapy for initially unresectable hepatocellular carcinomaWen, Yaohong; Fu, Shunjun; He, Guolin; Cai, Lei; Liu, Yahong; Li, Xinmin; Xu, Yuyan; Wang, Chunming; Zhong, Kaihang; Zhang, Cheng; Xie, Qingyu; Pan, MingxinAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: A retrospective analysis.Dong, Wei; Zhang, Songyan; Huo, Zhuoni; Lu, Junrong; Liu, Haishi; Wang, Ping; Zhang, YubaoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Tyrosine kinase inhibitors and/or immune checkpoint inhibitors is required for improving efficacy of transarterial chemoembolization for hepatocellular carcinoma: A large-scale multicenter real-world study of 582 patients
5阅读
